IMU will need sustain clinical trial updates which is why this "coming months" is important with Azer-Cel and in particular OASIS release post consolidation when the market haven't value any development in the last 18 months. Only the clinical trial update for Azer-Cel was sell on news, I suspect Precision got hold of the result with some strange buying in the lead up to the announcement and dumping right after.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)